Merck & Co., Inc. (MRK) — closed signal from January 30, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on April 30, 2026.
Predicted vs. what happened
What happened
Reached its target in 5 days.
The thesis — published January 30, 2026
Merck is a defensive healthcare stock with an upcoming earnings report on Feb 3 that could change how investors view it. The price has been weak but looks steadier; if the report is clean, the shares might bounce in the next few months as people shift into safer stocks. But drug-company updates and guidance can move shares fast, so wait for the market reaction and keep position size small if expectations fall.
Primary drivers
- Earnings can lower uncertainty and reset expectations
- Investors move to defensive stocks during market stress
- Big pharma trading means easier buying and selling
- Company pipeline updates and guidance can swing the stock
How it played out
MRK: target reached in 5 days
Lyra published MRK at $108.60 on 2026-01-30, with a short-term thesis for 10% growth. The thesis pointed to the Feb. 3 earnings report, a steadier price after weakness, possible defensive demand, big-pharma liquidity, and the risk that pipeline updates or guidance could move the stock quickly.
Inside the window, MRK reached the $119.46 target in 5 days. It later peaked at $125.14 on 2026-02-25, a 15.2% gain. By 2026-04-30 it ended at $109.18. The published thesis played out, but the move did not hold near the peak through the close.
What happened during the window
On Feb. 3, 2026, Merck reported fourth-quarter 2025 revenue of $16.4 billion and adjusted earnings per share of $2.04. It also gave 2026 revenue guidance of $65.5 billion to $67.0 billion and adjusted earnings guidance of $5.00 to $5.15.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.